Company Overview

Biotage AB (publ) provides separation technologies in the areas of organic and analytical chemistry, biomolecules, and industrial scale up applications. The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, and work-up products; flash systems and flash system accessories; normal, reversed, and speciality phase cartridges; plasmid purification solutions; and metal scavengers and reagents, as well as accessories and spare parts. It also provides sample preparation solutions in the clinical and bioanalytical, forensic and toxicology, doping control animal and human, environment, and food and agriculture areas, as well as consumables and systems; protein purification solutions, including antibody and tagged proteins purification, automation systems, and custom packing service, as well as ion exchange, reversed phase, normal phase, and gel filtration PhyTip columns. The company sells its products to pharmaceutical and biotechnical companies, contract research and manufacturing organizations, and government authorities and academic institutions, as well as clinical, forensic, and academic laboratories. It operates in 70 countries, which include Americas, Europe, the Middle East, Africa, and Asia Pacific. Biotage AB (publ) was founded in 1969 and is headquartered in Uppsala, Sweden.

  • Name

    Biotage AB (publ)

  • CEO

    Mr. Torben Jorgensen B.Sc.

  • Website

    www.biotage.com

  • Sector

    Life Sciences Tools and Services

  • Year Founded

    1969

Profile

  • Market Cap

    SEK 14.83B

  • EV

    SEK 14.76B

  • Shares Out

    80.05M

  • Revenue

    SEK 2,077M

  • Employees

    667

Margins

  • Gross

    62.73%

  • EBITDA

    23.5%

  • Operating

    17.86%

  • Pre-Tax

    15.07%

  • Net

    12.08%

  • FCF

    16.42%

Returns (5Yr Avg)

  • ROA

    11.27%

  • ROTA

    19.07%

  • ROE

    16.29%

  • ROCE

    15.97%

  • ROIC

    14.15%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    SEK 191

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    SEK 318M

  • Net Debt

    -SEK 64M

  • Debt/Equity

    0.07

  • EBIT/Interest

    9.05

Growth (CAGR)

  • Rev 3Yr

    21.94%

  • Rev 5Yr

    15.81%

  • Rev 10Yr

    16.29%

  • Dil EPS 3Yr

    3.01%

  • Dil EPS 5Yr

    3.33%

  • Dil EPS 10Yr

    15.57%

  • Rev Fwd 2Yr

    13.92%

  • EBITDA Fwd 2Yr

    13.7%

  • EPS Fwd 2Yr

    16.46%

  • EPS LT Growth Est

    19.6%

Dividends

  • Yield

  • Payout

    51%

  • DPS

    SEK 1.6

  • DPS Growth 3Yr

    2.17%

  • DPS Growth 5Yr

    1.3%

  • DPS Growth 10Yr

    10.31%

  • DPS Growth Fwd 2Yr

    14.38%

OM:BIOT